Literature DB >> 3391217

Lipoprotein profiles at different stages of the nephrotic syndrome.

U Querfeld1, A Gnasso, W Haberbosch, J Augustin, K Schärer.   

Abstract

We investigated lipoprotein profiles in 24 children with normal renal function at different stages of the idiopathic nephrotic syndrome (NS). Four groups of patients were studied: (I) steriod-resistant NS with persistent proteinuria; (II) untreated steroid-sensitive NS during a relapse; (III) steroid-sensitive NS in remission induced by steroid-treatment; (IV) steroid-sensitive NS in long-term remission without therapy. Triglycerides (TG), cholesterol (CHOL), and phospholipids (PLP) were measured in plasma as well as in the lipoprotein fractions of very low (VLDL), intermediate (IDL), low (LDL) and high density (HDL). Apoproteins (Apo) AI, AII, B and C-apoproteins were measured in patients of groups I and IV. Results were compared to those obtained in 24 healthy control subjects. All patients with active NS (groups I-III) had significantly elevated CHOL levels. TG and CHOL in the VLDL, IDL, LDL, and CHOL in HDL2, but not HDL3 were inversely correlated with the serum albumin level. Patients with active NS had increased concentrations of TG and CHOL in lipoprotein fractions of lower density. Total and fractionated HDL-CHOL was not significantly different from control levels in any group. Patients in group I had significantly reduced Apo AI levels, whereas an increase of Apo AI and Apo AII in HDL3 and of most C-apoproteins in both HDL fractions was observed in patients of group IV. While changes in HDL apoprotein composition during long-term remission are of yet unknown clinical significance, our data indicate an increased risk of atherosclerosis only in those paediatric patients with persistent steroid-resistant NS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391217     DOI: 10.1007/bf00442685

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  46 in total

1.  Origin of hypercholesterolemia in chronic experimental nephrotic syndrome.

Authors:  A C Goldberg; F G Eliaschewitz; E C Quintão
Journal:  Kidney Int       Date:  1977-07       Impact factor: 10.612

2.  An approximate distribution of estimates of variance components.

Authors:  F E SATTERTHWAITE
Journal:  Biometrics       Date:  1946-12       Impact factor: 2.571

3.  Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome.

Authors:  E Gherardi; E Rota; S Calandra; R Genova; A Tamborino
Journal:  Eur J Clin Invest       Date:  1977-12       Impact factor: 4.686

4.  Ischaemic heart-disease as a complication of nephrotic syndrome.

Authors:  G M Berlyne; N P Mallick
Journal:  Lancet       Date:  1969-08-23       Impact factor: 79.321

5.  Serum and urinary lipoproteins in the human nephrotic syndrome: evidence for renal catabolism of lipoproteins.

Authors:  V G Shore; T Forte; H Licht; S B Lewis
Journal:  Metabolism       Date:  1982-03       Impact factor: 8.694

Review 6.  Lipoprotein metabolism in experimental nephrosis.

Authors:  J B Marsh
Journal:  J Lipid Res       Date:  1984-12-15       Impact factor: 5.922

7.  The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study.

Authors:  J Zimmerman; M Fainaru; S Eisenberg
Journal:  Metabolism       Date:  1984-06       Impact factor: 8.694

8.  The in vitro formation of HDL2 during the action of LCAT: the role of triglyceride-rich lipoproteins.

Authors:  H Dieplinger; R Zechner; G M Kostner
Journal:  J Lipid Res       Date:  1985-03       Impact factor: 5.922

9.  Lipoprotein profiles in a heterogeneous group of patients with nephrotic syndrome.

Authors:  J Michaeli; H Bar-On; E Shafrir
Journal:  Isr J Med Sci       Date:  1981-11

10.  High density lipoproteinuria in nephrotic syndrome.

Authors:  S G de Mendoza; M L Kashyap; C Y Chen; R F Lutmer
Journal:  Metabolism       Date:  1976-10       Impact factor: 8.694

View more
  3 in total

Review 1.  Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.

Authors:  Mona Khurana; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2015-03-24       Impact factor: 3.714

2.  Paraoxonase Activity and Lipid Profile in Paediatric Nephrotic Syndrome: A Cross-sectional Study.

Authors:  Vijayetha P Patil; Anuradha B Patil; Vidya S Patil; Deepti G Ingleshwar
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 3.  Lipid changes in the nephrotic syndrome: new insights into pathomechanisms and treatment.

Authors:  G D'Amico
Journal:  Klin Wochenschr       Date:  1991-09-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.